Nonalcoholic fatty liver disease as a multi-systemic disease.
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. NAFLD includes a wide spectrum of liver conditions ranging from simple steatosis to nonalcoholic steatohepatitis and advanced hepatic fibrosis. NAFLD has been recognized as a hepatic manifestation of metabolic syndrome linked with insulin resistance. NAFLD should be considered not only a liver specific disease but also an early mediator of systemic diseases. Therefore, NAFLD is usually associated with cardiovascular disease, chronic kidney disease, type 2 diabetes, obesity, and dyslipidemia. NAFLD is highly prevalent in the general population and is associated with increased cardiovascular morbidity and mortality. The underlying mechanisms and pathogenesis of NAFLD with regard to other medical disorders are not yet fully understood. This review focuses on pathogenesis of NAFLD and its relation with other systemic diseases.
Hakan Fotbolcu, Department of Cardiology, Pendik BölgeHastanesi, Istanbul 34000, Turkey.
Hakan
H
Fotbolcu
Hakan Fotbolcu, Department of Cardiology, Pendik BölgeHastanesi, Istanbul 34000, Turkey.
Elçin
E
Zorlu
D000818:Animals; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D050171:Dyslipidemias / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000453:epidemiology; D065626:Non-alcoholic Fatty Liver Disease / Q000175:diagnosis / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D009765:Obesity / Q000453:epidemiology; D011379:Prognosis; D051436:Renal Insufficiency, Chronic / Q000453:epidemiology; D012307:Risk Factors; D020181:Sleep Apnea, Obstructive / Q000453:epidemiology
Cardiovascular effect; Insulin resistance; Multi-systemic disease; Nonalcoholic fatty liver disease; Obesity